Aequus Pharmaceuticals Inc. (CVE:AQS – Get Free Report) hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as C$0.01 and last traded at C$0.01, with a volume of 26059 shares. The stock had previously closed at C$0.01.
Aequus Pharmaceuticals Trading Down 50.0 %
The firm has a market cap of C$663,150.00, a P/E ratio of -0.50 and a beta of -0.02. The company has a debt-to-equity ratio of 138.88, a quick ratio of 0.46 and a current ratio of 0.07. The firm has a fifty day moving average of C$0.01 and a 200-day moving average of C$0.01.
Aequus Pharmaceuticals Company Profile
Aequus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease.
See Also
- Five stocks we like better than Aequus Pharmaceuticals
- The 3 Best Fintech Stocks to Buy Now
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- How Technical Indicators Can Help You Find Oversold Stocks
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- How Investors Can Find the Best Cheap Dividend Stocks
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Aequus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aequus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
